LSD for depression shows mixed Phase 3 results as Definium's data highlights remission gains, weaker response rates, and unresolved comparisons with psilocybin

LSD-assisted therapy for depression is presented through Definium's Phase 3 data, with the key finding that remission outcomes appear stronger than simple response rates and may compare favorably with psilocybin on some measures. The central question is not whether one psychedelic is universally better, but how trial design, endpoints, and patient populations shape apparent efficacy. Definium's results are framed around depression treatment outcomes that can look different depending on whether improvement, response, or remission is emphasized. Comparisons with psilocybin remain tentative because cross-trial contrasts are vulnerable to differences in dosing models, psychotherapy support, baseline severity, and follow-up windows. LSD's potential advantages are weighed against uncertainty in the evidence base, suggesting that investors, clinicians, and observers should read headline efficacy claims carefully. Regulatory prospects and commercial positioning depend less on simplistic substance rankings than on how durable benefit, safety, and trial methodology hold up under scrutiny.